Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy? [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
This milestone represents the first-ever global Phase 3 data for an in vivo CRISPR therapy, proving the technology is clinically viable. Intellia Therapeutics stock has been a lucrative investment in 2026, currently up more than 50% versus the start of this year. More News from Barchart Mega-Cap Earnings, FOMC and Other Key Things to Watch this Week Spirit Airlines Stock Is Ready for Takeoff Thanks to Trump, but Can This Plane Stay in the Sky? Intel Could Still Be Undervalued Based on Strong Free Cash Flow Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! www.barchart.com Why Intellia Therapeutics Stock Rallied Today According to Intellia Therapeutics, its therapy lonvoguran ziclumeran (lonvo-z) achieved a remarkable 87% reduction in monthly attack rates compared to a placebo. Even more impressive, 62% of patients remained entirel
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics (NTLA) had its price target raised by Citizens Jmp from $28.00 to $30.00. They now have a "market outperform" rating on the stock.MarketBeat
- Intellia Therapeutics (NTLA) had its "sell" rating reaffirmed by The Goldman Sachs Group, Inc..MarketBeat
- Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt [Seeking Alpha]Seeking Alpha
- Intellia Therapeutics (NTLA) had its "outperform" rating reaffirmed by Citigroup Inc..MarketBeat
- Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA Filing [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 2/26/26 - Beat
NTLA
Sec Filings
- 4/27/26 - Form 424B5
- 4/27/26 - Form 8-K
- 4/10/26 - Form 8-K
- NTLA's page on the SEC website